LAS VEGAS, Nevada — Risankizumab (Skyrizi, AbbVie) provides early and lasting benefits for patients with Crohn’s disease, phase 3 trials
Home »
Neurologic Drug Prices Jump 50% in Five Years
Medicare payments for branded neurologic drugs jumped 50% over a 5-year period, while claims for these medications increased by just